H.S.; Fuchs, K.; Sullivan, L.; Comstock, C.H.; Sade, G.
H.S.; Fuchs, K.; Sullivan, L.; Comstock, C.H.; Sade, G.R.; Eddleman, K.; et al. Part of second-trimester genetic sonography soon after Down syndrome screening. Obstet. Gynecol. 2009, 114, 1189sirtuininhibitor196. 18. Miguelez, J.; I-309/CCL1 Protein custom synthesis Maymon, R.; Cuckle, H.; Zugaib, M.; Bunduki, V.; Herman, A. Model predicted functionality of second trimester Down syndrome screening with ultrasound prenasal thickness. J. Ultrasound Med. 2010, 29, 1741sirtuininhibitor747. 19. Johnson, J.; Pastuck, M.; Metcalf, A.; Nilsson, C.; Connors, G.; Krause, R.; Wilson, D.; Cuckle, H. New approaches to 1st trimester Down’s syndrome screening working with more serum MCP-4/CCL13 Protein Purity & Documentation markers and cell totally free DNA. Prenat. Diagn. 2013, 33, 1044sirtuininhibitor049. 20. Borrell, A.; Mercade, I.; Casals, E.; Borobio, V.; Seres, A.; Soler, A.; Fortuny, A.; Cuckle, H. Combining fetal nuchal fold thickness with second trimester biochemistry to screen for trisomy 21. Ultrasound Obstet. Gynecol. 2007, 30, 941sirtuininhibitor45. 21. Benn, P.A.; Kaminsky, L.M.; Ying, J.; Borgida, A.F.; Egan, J.F. Combined second-trimester biochemical and ultrasound screening for Down syndrome. Obstet. Gynecol. 2003, 100, 1168sirtuininhibitor176. 22. Cuckle, H.; Maymon, R. Down syndrome danger calculation for a twin fetus taking account in the nuchal translucency within the co-twin. Prenat. Diagn. 2010, 30, 827sirtuininhibitor33. 23. Wright, D.; Syngelaki, A.; Staboulidou, I.; Cruz Jde, J.; Nicolaides, K.H. Screening for trisomies in dichorionic twins by measurement of fetal nuchal translucency thickness in line with the mixture model. Prenat. Diagn. 2011, 31, 16sirtuininhibitor1. 24. Cleary-Goldman, J.; Rebarber, A.; Krantz, D.; Hallahan, T.; Saltzman, D. First-trimester screening with nasal bone in twins. Am. J. Obstet. Gynecol. 2008, 199, e1 three.J. Clin. Med. 2014,25. Maiz, N.; Staboulidou, I.; Leal, A.M.; Minekawa, R.; Nicolaides, K.H. Ductus venosus Doppler at 11 to 13 weeks of gestation inside the prediction of outcome in twin pregnancies. Obstet. Gynecol. 2009, 113, 860sirtuininhibitor65. 26. Cuckle, H.S.; van Lith, J.M.M. Proper biochemical parameters in first trimester screening for Down’s syndrome. Prenat. Diagn. 1999, 19, 505sirtuininhibitor12. 27. Christiansen, M.; Larsen, O. An increase in cost-effectiveness of initial trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat. Diagn. 2002, 22, 482sirtuininhibitor86. 28. Canick, J.A.; Palomaki, G.E.; Kloza, E.M.; Lambert-Messerlian, G.M.; Haddow, J.E. The effect of maternal plasma DNA fetal fraction on subsequent generation sequencing tests for prevalent fetal aneuploidies. Prenat. Diagn. 2013, 33, 667sirtuininhibitor74. 29. Benn, P.; Cuckle, H. Theoretical performance of non-invasive prenatal testing for chromosome imbalances employing counting of cell-free DNA fragments in maternal plasma. Prenat. Diagn. 2014, in press. 30. Benn, P. Non-invasive prenatal diagnosis working with cell no cost DNA in maternal plasma; current developments and future prospects. J. Clin. Med. 2014, two, in press. 31. Cuckle, H.; Benn, P.; Pergament, E. Maternal cfDNA screening for Down’s syndrome–A expense sensitivity analysis. Prenat. Diagn. 2013, 33, 636sirtuininhibitor42. 32. Nicolaides, K.H.; Syngelaki, A.; Poon, L.C.; Gil, M.M.; Wright, D. First-Trimester Contingent Screening for Trisomies 21, 18 and 13 by Biomarkers and Maternal Blood Cell-Free DNA Testing. Fetal Diagn. Ther. 2013, 35, doi:10.1159/000356066. 33. Spencer, K.; Nicolaides, K.H. A initially trimester tr.
